BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Qi HJ, Li LF. New Biologics for the Treatment of Atopic Dermatitis: Analysis of Efficacy, Safety, and Paradoxical Atopic Dermatitis Acceleration. Biomed Res Int 2021;2021:5528372. [PMID: 34195265 DOI: 10.1155/2021/5528372] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Lé AM, Torres T. OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis-Focus on Rocatinlimab and Amlitelimab. Pharmaceutics 2022;14. [PMID: 36559247 DOI: 10.3390/pharmaceutics14122753] [Reference Citation Analysis]
2 Tsai Y, Tsai T. Overlapping Features of Psoriasis and Atopic dermatitis: From Genetics to Immunopathogenesis to Phenotypes. IJMS 2022;23:5518. [DOI: 10.3390/ijms23105518] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Jeong NH, Lee S, Choi YA, Song KS, Kim SH. Inhibitory Effects of Euscaphic Acid in the Atopic Dermatitis Model by Reducing Skin Inflammation and Intense Pruritus. Inflammation 2022. [PMID: 35257273 DOI: 10.1007/s10753-022-01652-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]